Press Releases

(Singapore, September 24, 2025) – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, will hold a series of events in Singapore from September 24-26, 2025. These events included an exclusive tour of the Singapore site, a closed-door symposium, high-level seminars, and the 2025 Biopharmaceutical Bioprocess Development Summit. Among these, the tour of the WuXi XDC Singapore site and the industry closed-door symposium concluded successfully today, bringing together partners from the biopharmaceutical industry to gain insights into advanced bioconjugates manufacturing process and promote international cooperation.

WuXi XDC’s Singapore Site Tour
During this tour, the Singapore site, a cornerstone of WuXi XDC’s global strategy and commercial manufacturing, showcased its one-stop, end-to-end production capabilities integrating antibody intermediates, bioconjugate drug substance, and drug products. The tour attracted active participation from dozens of international pharmaceutical giants and biotech companies. The tour areas covered the key components, including antibody intermediates & bioconjugate drug substance facilities, drug product facilities, quality control and mechanical areas.
 

 
Singapore Site: Antibody Intermediates & Bioconjugate Drug Substance for Commercial Manufacturing

Dual function XBCM3 facility is designed with capacity to produce 50 liters to 2,000 liters per batch for antibody intermediates, or up to 2,000 liters per batch for bioconjugate drug substance. The facility is equipped with advanced manufacturing processes and a rigorous quality control system.
 
XBCM4 facility is designed with capacity of up to 500 liters of bioconjugate drug substance per batch.
 
Singapore Site: Bioconjugate Drug Product for Commercial Manufacturing

The XDP4 facility is equipped with 1×10 ㎡ & 2×30 ㎡ lyophilizers and designed to produce eight million vials of bioconjugate drug products per year in liquid or lyophilized form. The filling line integrates multiple key technologies: automatic tail fluid emptying, 100% online weight check, non-vacuum stoppering, and high-speed filling up to 300 vials per minute etc. Its dual-camera inspection system enables real-time rejection of products with missing or high stopper online, ensuring high-quality output.Dr. Hu highlighted that WuXi XDC’s high-quality services have been demonstrated in numerous benchmark cases. For instance, in the case of a certain biopharmaceutical company, WuXi XDC provided end-to-end support from the IND stage to critical BLA preparation, and utilized its proprietary WuXiDARx™ platform to optimize molecular structures and enhance efficacy and PK profile. This professional technical support and efficient service response earned strong recognition, leading the customer to entrust WuXi XDC with multiple ADC programs—a testament to the deep mutual trust between the two parties.

Located in the Tuas Biomedical Park, the Singapore site exemplifies the “WuXi Speed” again in its construction to meet the growing demands of global customers. The Singapore site has achieved mechanical completion in June 2025, and is expected to achieve GMP release in the first half of 2026. Leveraging Singapore’s strong biomanufacturing industry cluster and policy advantages, WuXi XDC will provide comprehensive, high-quality commercial manufacturing solutions for global partners. At the same time, it will complement WuXi XDC’s capacity in Wuxi, China, meeting the diverse bioconjugate manufacturing needs of customers and continuously consolidating its leading position in the global CRDMO field.
 
Closed-Door Symposium

After the site tour, WuXi XDC held a closed-door symposium, bringing together dozens of experts and corporate executives to deeply discuss key issues in the bioconjugate field. The meeting focused on industry frontier trends and one-stop CRDMO service, looking beyond traditional ADCs to explore new directions in bioconjugates and uncover potential growth points in the industry.
 

 
Experts discussed bioconjugates discovery, emerging industry trends and global supply chain. Participants analyzed the current global supply chain status of the bioconjugates outsourcing market, discussing how to optimize layout, ensure quality and supply chain stability, and respond to an increasingly complex market environment. As the global leader in the bioconjugates CRDMO field, WuXi XDC, on the one hand, is enhancing “All-in-One” manufacturing capabilities in Wuxi site, and on the other hand, is building a commercial manufacturing site in Singapore to expand its global service network, in order to meet the diverse supply chain demands of customers.

 
WuXi XDC has been deeply engaged in the field of bioconjugates CRDMO for years, committed to providing global customers with integrated solutions covering the entire bioconjugates life cycle, accelerating the drug R&D process, reducing costs, and offering high-quality products and services to customers, working together to promote the vigorous development of the industry.
 


 
As a co-organizer of 2025 Biopharmaceutical Bioprocess Development Summit, WuXi XDC will also host a special XDC Innovation and Development forum on September 25. At that time, top global experts will share cutting-edge research results and industrialization practice experiences, and deeply discuss technical difficulties and innovation directions, leveraging Singapore’s industrial advantages and the summit to deepen technical exchanges and provide guidance and path references.
 
About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com
 
Contacts
Investor: wuxixdc.ir@wuxibiologics.com

Media: wuxixdc_pr@wuxibiologics.com

BD: wuxixdc_info@wuxibiologics.com